Simplify Vettafi Private Credit Strategy ETF (PCR) closed at $17.86 on October 30, 2026, down 0.3% from the previous close, on volume of 1,988 shares (30-day average 624).
Data as of October 30, 2026.
No headlines found.
Net Asset Value Restatement for Simplify VettaFi Private Credit Strategy ETF (PCR)
Globe Newswire (Thu, 3-Sep 4:43 PM ET)
The Simplify VettaFi Private Credit Strategy ETF (PCR) seeks income and capital appreciation by investing in a private credit strategy plus a credit hedge derivatives strategy. The private credit strategy focuses on business development companies (BDCs) and publicly-traded closed end funds (CEFs) that primarily invest in the private credit sector. Credit hedging is primarily through a proprietary long/short hedge based on total return swaps of "quality" and "junk" equities. The objective of the fund is to invest at least 80% of the Fund's net assets in securities included in the VettaFi Private Credit Index (the "Index") and/or through instruments that seek to track the returns of the constituents of the Index. However, the Fund intends to execute its investment strategy predominantly through swaps that have returns that track the returns of the constituents of the Index. The Index is designed to track the performance of private credit instruments held by U.S. registered publicly-traded business development companies ("BDCs") and U.S. registered publicly-traded closed-end funds ("CEFs") that each primarily invest in private credit assets. A BDC or CEF primarily invests in private credit if more than 50% of its investment portfolio is invested in private credit assets.
Simplify Vettafi Private Credit Strategy ETF trades on the ARCA stock market under the symbol PCR.
As of October 30, 2026, PCR stock price declined to $17.85 with 1,988 million shares trading.
PCR has a market cap of $2.23 million. This is considered a Sub-Micro Cap stock.
PCR has underperformed the market in the last year with a return of -16.6%, while the SPY ETF gained +12.3%. In the last 3 month period, PCR fell short of the market, returning -2.7%, while SPY returned +2.1%. However, in the most recent 2 weeks PCR has outperformed the stock market by returning +0.2%, while SPY returned -1.0%.
PCR support price is $17.72 and resistance is $18.09 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PCR shares will trade within this expected range on the day.
